Capital Research Global Investors
GSK icon

Capital Research Global Investors’s GSK GSK Stock Holding History

Capital Research Global Investors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,794,427
Closed -$77.4M – 447
2025
Q3 		$77.4M Buy
1,794,427
+17,615
+1% +$688K 0.01% 315
2025
Q2 		$68.2M Buy
1,776,812
+14,654
+0.8% +$560K 0.01% 320
2025
Q1 		$68.3M Buy
1,762,158
+2,950
+0.2% +$108K 0.01% 333
2024
Q4 		$59.5M Buy
1,759,208
+4,715
+0.3% +$170K 0.01% 347
2024
Q3 		$71.7M Hold
1,754,493
– – 0.01% 312
2024
Q2 		$67.5M Buy
1,754,493
+1,458
+0.1% +$61.3K 0.01% 313
2024
Q1 		$75.2M Hold
1,753,035
– – 0.02% 308
2023
Q4 		$65M Hold
1,753,035
– – 0.02% 304
2023
Q3 		$63.5M Buy
1,753,035
+685
+0% +$24.3K 0.02% 311
2023
Q2 		$62.5M Buy
1,752,350
+1,032
+0.1% +$37K 0.02% 315
2023
Q1 		$62.3M Buy
1,751,318
+1,140
+0.1% +$39.9K 0.02% 311
2022
Q4 		$61.5M Sell
1,750,178
-88
-0% -$2.93K 0.02% 313
2022
Q3 		$51.5M Sell
1,750,266
-2,703,892
-61% -$102M 0.02% 316
2022
Q2 		$242M Sell
4,454,158
-1,013
-0% -$55.9K 0.08% 193
2022
Q1 		$243M Buy
4,455,171
+161
+0% +$8.74K 0.06% 224
2021
Q4 		$246M Sell
4,455,010
-603
-0% -$31.4K 0.05% 227
2021
Q3 		$213M Buy
4,455,613
+574
+0% +$28.8K 0.05% 242
2021
Q2 		$222M Sell
4,455,039
-117,688
-3% -$5.65M 0.05% 234
2021
Q1 		$204M Buy
4,572,727
+821
+0% +$37.3K 0.05% 242
2020
Q4 		$210M Buy
4,571,906
+576,903
+14% +$26.5M 0.05% 239
2020
Q3 		$188M Buy
3,995,003
+291,087
+8% +$14.6M 0.06% 221
2020
Q2 		$189M Buy
3,703,916
+3,703,757
+2,329,407% +$190M 0.06% 214
2020
Q1 		$7K Buy
+159
New +$8.48K ﹤0.01% 394

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors's GSK Position: Q4 2025 in Review

Capital Research Global Investors sold out of GSK (GSK) in Q4 2025, closing a stake of 1,794,427 shares — an estimated $77.4M sold.

Capital Research Global Investors first reported a position in GSK in Q1 2020 and held it in 23 quarters. The position peaked at $246M in Q4 2021. 996 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

  • Capital Research Global Investors reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
  • Capital Research Global Investors sold 1,794,427 GSK shares in Q4 2025, an estimated $77.4M.
  • Capital Research Global Investors first reported a position in GSK in Q1 2020 and held it in 23 quarters.
  • Capital Research Global Investors's GSK position peaked at $246M in Q4 2021.
  • 996 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Capital Research Global Investors's 13F filing for Q4 2025, filed 11 Feb 2026.